UnknownPhase 2NCT04161014
The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial
Studying Asbestos intoxication
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Holdsworth House Medical Practice
- Principal Investigator
- Deborah Yates, A/ProfHoldsworth House Medical Practice
- Intervention
- Nintedanib 150 MG [Ofev](drug)
- Enrollment
- 100 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2025
Study locations (1)
- Holdsworth House Medical Practice, Sydney, New South Wales, Australia
Collaborators
Boehringer Ingelheim
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04161014 on ClinicalTrials.govOther trials for Asbestos intoxication
Additional recruiting or active studies for the same condition.